#	Pagina
attuale pagina	/open-h2020/projects/212345/results.html

Report

Teaser, summary, work performed and final results

Periodic Reporting for period 1 - iNanoBIT (Integration of Nano- and Biotechnology for beta-cell and islet Transplantation)

Teaser

Summary

The iNanoBIT project is aimed to apply nanotechnologies for imaging porcine pancreatic islet cellular transplants and induced pluripotent stem cell-derived beta-cells and subsequent regenerative processes in vivo in a porcine model.
Our focus is on diabetes, as one of the most challenging and economically important areas of medicine with very high level of importance for society. Specifically, we will provide and evaluate a technology which would support the regenerative medicinal solutions for Type 1 diabetes (T1D), but we expect a much broader overall applicability of the new tool-box for cellular/tissue imaging methods enabling follow up of various medical interventions for, e.g., osteochondral, hepatic, renal, lung, cardiac or brain cell therapy interventions. This imaging approach will offer the potential for earlier detection of rejection or dysfunction of transplanted cells, tissues or organs, which would enable an earlier medical decision on switching to alternative therapeutic options for individual patients.
The project develops:
1) novel highly sensitive nanotechnology-based imaging approaches allowing for monitoring of survival, engraftment, proliferation, function and whole body distribution of the cellular transplants in a preclinical porcine model with excellent translational potential to humans;
2) develop and validate the application of state-of-the-art imaging technologies facilitating the provision of new regenerative therapies to preclinical large animal models and patients;
3) directly contribute to the opening of a new market sector for
i) imaging equipment (SPECT, PET/MR, optoacoustic imaging in preclinical large animal models and patients),
ii) nano-imaging molecule supplies (nanomolecules allowing multimodality imaging of specific cell types with high sensitivity),
iii) validated transplantable in vitro differentiated human beta-cells and porcinexenotransplant islets thus will reinforce the European healthcare supply chain for regenerative medicinal products.
The iNanoBIT project will provide the currently missing toolbox for preclinical/clinical testing for a safe translation of regenerative medicinal cellular and tissue products, currently under preclinical and clinical trials, which is vital for the competitiveness of the European healthcare sector in this fast-growing area. The consortium of 5 SME and 3 Academic partners is coordinated and driven by the industrial partners from the field of nanotechnology, imaging and stem cell technologies, providing a perfect match and unique combination addressing the scope and expected impact of the call and providing TRL 3/4 starting points for the key technological elements, and expect to arrive to TRL6 levels of validated technologies ready for marketing by the end of the project.

Work performed

The project made excellent progress in all aspects, by developing novel nanotechnology-based tools for monitoring beta-cell and islet cellular transplants, currently under testing for their interaction with cells and medical devices ex-situ and after transplantation. New, highly sensitive imaging equipments for SPECT and optoacoustic imaging have been developed, improving the previous designs. In accordance with the plans, genetically modified human pluripotent stem cell lines and pigs have been produced for better traceability of the transplanted cells and islets, respectively.

Final results

Significant progress beyond the current state-of-the-art have been made in all aspects of biological and nanotechnological resources, imaging equipment and medical device development. The combination of such advances are expected to create novel medical options to treat type 1 diabetes by regenerative medicine approaches, which would alleviate the burden of disease on society, especially due to diabetes-related medical complications, shortening the life-span and decreasing the quality of life of many.